No­var­tis' plans to wres­tle Eylea mar­ket share take a hit as Beovu is linked to safe­ty con­cerns

While Re­gen­eron’s flag­ship eye ther­a­py Eylea hur­tles to­wards a patent cliff, the sales of its main ri­val — No­var­tis’ Beovu — could be taint­ed by safe­ty con­cerns.

On Sun­day night, Chica­go-based Amer­i­can So­ci­ety of Reti­na Spe­cial­ists (ASRS) is­sued a note to mem­bers about 14 cas­es of reti­nal vas­culi­tis (in­clud­ing 11 cas­es of oc­clu­sive reti­nal vas­culi­tis) — a sight-threat­en­ing in­flam­ma­to­ry eye con­di­tion that in­volves the reti­nal ves­sels — across 46,000 in­jec­tions ad­min­is­tered since Beovu’s launch in No­vem­ber 2019, Wall Street an­a­lysts re­port­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER